Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004679995> ?p ?o ?g. }
- W2004679995 endingPage "152" @default.
- W2004679995 startingPage "143" @default.
- W2004679995 abstract "The management of relapsed/refractory mantle cell lymphoma (MCL) remains a clinical challenge. A standard second-line treatment for relapsed/refractory MCL does not exist. Management of relapsed/refractory MCL requires an individualized treatment approach, incorporating factors such as: functional status, prior treatments, response to prior therapies, and disease biology. Generally, there are two categories of salvage therapy; the first, non-cross-resistant cytotoxic chemotherapeutic agents and, the second, pathway-targeted agents. For transplant eligible patients, the optimal therapy usually consists of salvage, remission re-induction phase followed, whenever possible, by a consolidation phase. Bendamustine and/or high dose cytarabine plus rituximab based chemotherapy represent the most common salvage therapy with an overall response rate of 70-80%. Consolidation with a reduced intensity conditioning allogeneic stem cell transplantation represents the only potentially curative treatment. Overall survival ranges from 30% to 50% at 5 years with this approach. For transplant ineligible patients, ibrutinib is the most effective treatment with an overall response rate of almost 70% and median response duration of 17.5 months. Lacking an effective consolidation, this approach is not considered curative. In this review we characterize the main therapeutic approaches available in this setting and summarize our preferred clinical treatment approach." @default.
- W2004679995 created "2016-06-24" @default.
- W2004679995 creator A5034628611 @default.
- W2004679995 creator A5045167741 @default.
- W2004679995 creator A5055226769 @default.
- W2004679995 creator A5074706721 @default.
- W2004679995 creator A5089206024 @default.
- W2004679995 date "2015-05-01" @default.
- W2004679995 modified "2023-10-18" @default.
- W2004679995 title "Lifting the mantle: Unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma" @default.
- W2004679995 cites W1826464020 @default.
- W2004679995 cites W1883328448 @default.
- W2004679995 cites W1969461242 @default.
- W2004679995 cites W1977342543 @default.
- W2004679995 cites W1984118485 @default.
- W2004679995 cites W1985343909 @default.
- W2004679995 cites W1986483184 @default.
- W2004679995 cites W1988250187 @default.
- W2004679995 cites W1990883298 @default.
- W2004679995 cites W1993715323 @default.
- W2004679995 cites W1999582975 @default.
- W2004679995 cites W2003327619 @default.
- W2004679995 cites W2009937603 @default.
- W2004679995 cites W2012098025 @default.
- W2004679995 cites W2026122699 @default.
- W2004679995 cites W2031133932 @default.
- W2004679995 cites W2038509045 @default.
- W2004679995 cites W2039431106 @default.
- W2004679995 cites W2042675584 @default.
- W2004679995 cites W2044348066 @default.
- W2004679995 cites W2047164612 @default.
- W2004679995 cites W2052220490 @default.
- W2004679995 cites W2056407789 @default.
- W2004679995 cites W2059492063 @default.
- W2004679995 cites W2070073293 @default.
- W2004679995 cites W2077494567 @default.
- W2004679995 cites W2082584333 @default.
- W2004679995 cites W2085346499 @default.
- W2004679995 cites W2087137028 @default.
- W2004679995 cites W2088463205 @default.
- W2004679995 cites W2089772861 @default.
- W2004679995 cites W2090377851 @default.
- W2004679995 cites W2094479591 @default.
- W2004679995 cites W2095669071 @default.
- W2004679995 cites W2097913548 @default.
- W2004679995 cites W2098002594 @default.
- W2004679995 cites W2100608938 @default.
- W2004679995 cites W2101874491 @default.
- W2004679995 cites W2103255742 @default.
- W2004679995 cites W2104434365 @default.
- W2004679995 cites W2105352757 @default.
- W2004679995 cites W2106904404 @default.
- W2004679995 cites W2111611512 @default.
- W2004679995 cites W2112497073 @default.
- W2004679995 cites W2116090592 @default.
- W2004679995 cites W2120755425 @default.
- W2004679995 cites W2123185965 @default.
- W2004679995 cites W2124235514 @default.
- W2004679995 cites W2125684345 @default.
- W2004679995 cites W2125933401 @default.
- W2004679995 cites W2128812336 @default.
- W2004679995 cites W2130223796 @default.
- W2004679995 cites W2130883918 @default.
- W2004679995 cites W2131998596 @default.
- W2004679995 cites W2133934152 @default.
- W2004679995 cites W2139030094 @default.
- W2004679995 cites W2144863760 @default.
- W2004679995 cites W2146029333 @default.
- W2004679995 cites W2147422161 @default.
- W2004679995 cites W2148679457 @default.
- W2004679995 cites W2153569820 @default.
- W2004679995 cites W2153859516 @default.
- W2004679995 cites W2154066874 @default.
- W2004679995 cites W2155724413 @default.
- W2004679995 cites W2158466638 @default.
- W2004679995 cites W2162109567 @default.
- W2004679995 cites W2163690533 @default.
- W2004679995 cites W2169209759 @default.
- W2004679995 cites W2170362988 @default.
- W2004679995 cites W2171771895 @default.
- W2004679995 cites W2333943209 @default.
- W2004679995 doi "https://doi.org/10.1016/j.blre.2014.10.001" @default.
- W2004679995 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25468719" @default.
- W2004679995 hasPublicationYear "2015" @default.
- W2004679995 type Work @default.
- W2004679995 sameAs 2004679995 @default.
- W2004679995 citedByCount "8" @default.
- W2004679995 countsByYear W20046799952015 @default.
- W2004679995 countsByYear W20046799952016 @default.
- W2004679995 countsByYear W20046799952018 @default.
- W2004679995 crossrefType "journal-article" @default.
- W2004679995 hasAuthorship W2004679995A5034628611 @default.
- W2004679995 hasAuthorship W2004679995A5045167741 @default.
- W2004679995 hasAuthorship W2004679995A5055226769 @default.
- W2004679995 hasAuthorship W2004679995A5074706721 @default.
- W2004679995 hasAuthorship W2004679995A5089206024 @default.
- W2004679995 hasConcept C121332964 @default.
- W2004679995 hasConcept C126322002 @default.